A Revolutionary Step Toward Cleverer, Available Cancer Care
New York / Global — SCORPIO (Standard Clinical and Laboratory Features for Prognostication of Immunotherapy Outcomes) It’s a revolutionary AI powered tool which is designed to help doctors to determine which cancer patients are most likely to benefited from immune checkpoint inhibitors— relying merely on routine blood tests and normal clinical data. This tool is developed through a collaboration between researchers at Memorial Sloan Kettering Cancer Centre (MSK) and Mount Sinai, SCORPIO has the potential to access to life-saving immunotherapy while protecting patients from unnecessary side effects and expenses.
What Makes SCORPIO Special?
SCORPIO represents a meaningful shift in how treatment fittingness is appraised. Instead of using costly surgical procedures and lengthy tumour surgeries and genomic summarizing, this model influences widely available tests such as complete blood counts and metabolic panels—data already captured in most healthcare settings.
In straight comparisons, SCORPIO showed greater performance to two FDA-approved biomarkers—tumour mutational burden (TMB) and PD-L1 expression—in determining immunotherapy response.
Clinical Data & Validation
The SCORPIO model was built using retrospective records of more than 2,000 cancer patients, at MSK across 17 cancer types who receives checkpoint inhibitors, and validated on another ~2,100 independent cases.
Moreover, as of early 2025, findings were published in the prestigious journal Nature Medicine, detailing SCORPIO’s robust performance and outlining plans to broaden its accessibility to clinical settings worldwide. (
Accessibility and Global Impact
Dr. Luc Morris of MSK and Dr. Diego Chowell of Mount Sinai underscore SCORPIO’s potential to bring precision oncology to resource-limited environments. By using data already collected during routine care, SCORPIO makes sophisticated treatment decisions feasible regardless of infrastructure constraints.
Using AI-derived visions from regular blood tests, clinicians could better determine who stands to benefit from immunotherapy—reducing both costs and unnecessary exposure to opposing effects.
What’s Next?
Additional studies and validation are currently underway to expand SCORPIO’s scope and simplify combination into global healthcare systems. The goal is to make this tool a standard, widely reachable section of clinical decision-making in oncology.
Summary Table
| Aspect | Details |
| Tool Name | SCORPIO (AI-based prognostic model) |
| Data Used | Routine blood tests (CBC, metabolic panels) & clinical variables |
| Advantage | Non-invasive, cost-effective, globally deployable |
| Performance | Outperforms traditional biomarkers (TMB, PD-L1) |
| Validation | 4,000+ patients across multiple cancer types; published in Nature Medicine |
| Future Steps | Scale & integrate into routine oncology practice worldwide |
This development highlights how AI can influence everyday clinical data to improve cancer care—making treatments more targeted, affordable, and reachable.